FDA announces changes in drug center’s oncology office

Today, the U.S. Food and Drug Administration announced organizational changes within the office responsible for reviewing all drug and biologic applications for cancer therapies. The Center for Drug Evaluation and Research’s (CDER) Office of Oncology Drug Products has been reorganized and renamed the Office of Hematology and Oncology Products (OHOP).

FDA warns consumers of botulism risk in La Ruche tapenade, spreadable tomato paste

The FDA is warning consumers not to eat tapenade or spreadable dried tomato paste manufactured by the French food company La Ruche. French health authorities have reported an outbreak of botulism in France linked to the company’s products sold under the brand names “Les délices de Marie-Claire,” “Terre de Mistral” and Les Secrets d’Anaïs.” Eight adults are currently suffering from respiratory failure as a result of eating foods containing the neurotoxin produced by Clostridium botulinum.

BUI Natural Tofu Issues Allergy Alert on Undeclared Soy and Wheat in Their Shrimp Salad Roll and Vegetarian Salad Roll

BUI Natural Tofu, Portland, Oregon is voluntarily recalling their Shrimp Salad Roll and Vegetarian Salad Roll because they contain undeclared soy and wheat. People who have an allergy or severe sensitivity to soy and wheat run the risk of serious or life-threatening allergic reaction if they consume this product.
Read The Complete Story!

FDA Drug Safety Podcast for Healthcare Professionals: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria

On September 7, 2011, the Food and Drug Administration issued a Drug Safety Communication informing healthcare professionals that the Boxed Warning for the entire class of Tumor Necrosis Factor-alpha, or TNFa, blockers has been updated to include the risk of infection from two bacterial pathogens, Legionella and Listeria.

FDA Drug Safety Podcast for Healthcare Professionals: Updated drug labels for pioglitazone-containing medicines

On August 4, 2011, the Food and Drug Administration issued a Drug Safety Communication informing the public that the Agency has approved updated drug labels for the pioglitazone-containing medicines to include safety information that the use of pioglitazone for more than one year may be associated with an increased risk of bladder cancer.